Research Grade Casirivimab (DVV00304)
- Product NameResearch Grade Casirivimab (DVV00304)
- CAS2415933-42-3
- CBNumberCB412402160
- MW0
- MOL FileMol file
- MSDS FileSDS
Research Grade Casirivimab (DVV00304) Price
| Product number | Packaging | Price | Product description | Buy |
|---|---|---|---|---|
| Usbiological 591740 | 100ug | $602 | SARS-CoV-2 Spike Protein, Casirivimab Biosimilar PurifiedbyProteinA/Gaffinitychromatography.≥95%.Endotoxin:≤1EU/mg(LAL) |
Buy |
| Usbiological 591740 | 1mg | $991 | SARS-CoV-2 Spike Protein, Casirivimab Biosimilar PurifiedbyProteinA/Gaffinitychromatography.≥95%.Endotoxin:≤1EU/mg(LAL) |
Buy |
| Usbiological 591740 | 5mg | $1416 | SARS-CoV-2 Spike Protein, Casirivimab Biosimilar PurifiedbyProteinA/Gaffinitychromatography.≥95%.Endotoxin:≤1EU/mg(LAL) |
Buy |
| ChemScene CS-0621181 | 1mg | $379 | Casirivimab 99.54% |
Buy |
| ChemScene CS-0621181 | 5mg | $986 | Casirivimab 99.54% |
Buy |
Research Grade Casirivimab (DVV00304) Chemical Properties,Usage,Production
Uses
Casirivimab (REGN10933) is a human monoclonal antibody that targets the SARS-CoV-2 virus, which causes COVID-19. Casirivimab is ineffective against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), which alters the lung response of K18-hACE2 mice to the SARS-CoV-2 δ variant, effectively reducing viral load and improving symptoms[1][2].in vivo
Casirivimab (400 μg (Casirivimab and imdevimab), intraperitoneal injection, single dose) has shown positive results against the δ variant when used in combination with imdevimab, but its antiviral effectiveness appears to be weakened when dealing with the Omicron variant[2].
| Animal Model: | K18-hACE2 mice vaccinated with the SARS-CoV-2 δ or Omicron variant[2] |
| Dosage: | 400μg; single dose |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Decreased amount of subgenomic E RNA (sgE RNA), which reduced the viral load and improved lung pathology in δ. Weakened antiviral effectiveness in the body against Omicron. |
References
[1] Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Casirivimab. 2022 May 15. PMID:33226742[2] Lee Tatham, et al. Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case. Microbiol Spectr. 2024 Aug 6;12(8):e0391623. DOI:10.1128/spectrum.03916-23
Preparation Products And Raw materials
Research Grade Casirivimab (DVV00304) Suppliers
Global(16)Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| 27-027-83314682 13554138826 |
whsrtech@vip.163.com | China | 140 | 62 | |
| 18916372613 | yanzihan@shyuanye.com | China | 87240 | 60 | |
| 020-82000279 18988941452 |
YN_research@163.com | China | 2984 | 58 | |
| 0512-85557988 18662338937 |
frank.wang@greature.com.cn | China | 145 | 58 | |
| 010-60605840 | psaitong@jm-bio.com | China | 27756 | 58 | |
| 027-65279366 18108604356 |
products@biolabreagent.com | China | 9864 | 58 | |
| 13720134139 086-15871494362 13720134139 |
orders@jknbiochem.com | China | 7284 | 58 | |
| 15111215862 18229892877 |
3062105966@qq.com | China | 5577 | 58 | |
| 027-87008169 17762441161 |
info@atagenix.com | China | 9997 | 58 | |
| 86-17715515539 17715515539 |
James@geneleebio.com | China | 115 | 58 |
2415933-42-3, Research Grade Casirivimab (DVV00304)Related Search
PROMPT×
PROMPT
The WhatsApp is temporarily not supported in mainland China
The WhatsApp is temporarily not supported in mainland China
Cancel
Determine